Epigral Limited (Epigral), India’s leading integrated chemical manufacturer released its financial results for the quarter ended September 30, 2024. The company posted a robust growth in PAT for Q2FY25 at Rs 810 million, a jump of 111% as compared to Rs 380 million in Q2FY24. The company’s quarterly revenue rose by 32% to Rs 6.32 billion as against Rs 4.79 million recorded in Q2FY24. 

Epigral’s board has approved the expansion project of CPVC and Epichlorohydrin (ECH). CPVC resin capacity will be expanded to 1,50,000 TPA (Tonnes Per Annum) by adding another 75,000 TPA capacity and Epichlorohydrin (ECH) capacity will be enhanced to 1,00,000 TPA by adding another 50,000 TPA capacity, at the company’s Dahej facility in Gujarat. 

With this expansion, Epigral's total CPVC resin capacity will be elevated as the largest resin facility in the world and Epichlorohydrin will be the largest facility in India. 

CPVC and ECH expansions will meet the growing demand of these products in India. The organisation's move to further expand into CPVC resin and ECH production is consistent with the Government of India’s initiatives like Atmanirbhar Bharat and Make in India initiatives, which aim to make India more self-reliant.

With focus towards sustainability and environment, Epigral will be investing in Pure.rBrineTM technology for the recycling and reuse of by-product to use it as a raw material for other products. This will help in saving on waste discharge and reducing GHG emission from the overall supply chain.  Further, the company will benefit from cost rationalisation on account of strengthening integrated complex by consuming by-product as a raw material. 

Maulik Patel, Chairman and Managing Director, Epigral said, “Epigral witnessed the topline growth of 37% in H1FY25, on account of 17% sales volume growth coming from high value products of Derivatives and Specialty business, despite marginal drop in realisations for all the products. Revenue contribution from Derivative and Specialty business has reached to 59% in Q2FY25 vs 46% in Q2FY24”. 

“At Epigral we are focused on continuous growth and entering products which are 1st time in India. In line with that, we had entered into CPVC and ECH, import substitute products. Considering the acceptance of our product, market size and growing demand for both the products, we are excited to further expand in both the products and double it from our existing capacity.  The additional capacities are expected to get commissioned by H1 of FY2027 and these projects are expected to contribute FY2027 onwards. Our strategy to diversify into value added products, strengthening our integrated complex and sustained investment in capex will help us efficiency of scale and create value for our shareholders,” Patel added.